17
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A hexanucleotide ( GGGGCC) repeat expansion in C9ORF72 is the most common genetic contributor to amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Reduced expression of the C9ORF72 gene product has been proposed as a potential contributor to disease pathogenesis. Additionally, repetitive RNAs and dipeptide repeat proteins (DPRs), such as poly-GR, can be produced by this hexanucleotide expansion that disrupt a number of cellular processes, potentially contributing to neural degeneration. To better discern which of these mechanisms leads to disease-associated changes in patient brains, we analyzed gene expression data generated from the cortex and cerebellum. We found that transcripts encoding heat shock proteins (HSPs) regulated by the HSF1 transcription factor were significantly induced in C9ORF72-ALS/FTLD patients relative to both sporadic ALS/FTLD cases and controls. Treatment of human neurons with chemically synthesized DPRs was sufficient to activate a similar transcriptional response. Expression of GGGGCC repeats and also poly-GR in the brains of Drosophila lead to the upregulation of HSF1 and the same highly-conserved HSPs. Additionally, HSF1 was a modifier of poly-GR toxicity in Drosophila. Our results suggest that the expression of DPRs are associated with upregulation of HSF1 and activation of a heat shock response in C9ORF72-ALS/FTLD.

          Electronic supplementary material

          The online version of this article (10.1186/s40478-018-0555-8) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references19

          • Record: found
          • Abstract: found
          • Article: not found

          Molecular chaperones in protein folding and proteostasis.

          Most proteins must fold into defined three-dimensional structures to gain functional activity. But in the cellular environment, newly synthesized proteins are at great risk of aberrant folding and aggregation, potentially forming toxic species. To avoid these dangers, cells invest in a complex network of molecular chaperones, which use ingenious mechanisms to prevent aggregation and promote efficient folding. Because protein molecules are highly dynamic, constant chaperone surveillance is required to ensure protein homeostasis (proteostasis). Recent advances suggest that an age-related decline in proteostasis capacity allows the manifestation of various protein-aggregation diseases, including Alzheimer's disease and Parkinson's disease. Interventions in these and numerous other pathological states may spring from a detailed understanding of the pathways underlying proteome maintenance.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention.

            A hexanucleotide GGGGCC repeat expansion in the noncoding region of the C9ORF72 gene is the most common genetic abnormality in familial and sporadic amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The function of the C9ORF72 protein is unknown, as is the mechanism by which the repeat expansion could cause disease. Induced pluripotent stem cell (iPSC)-differentiated neurons from C9ORF72 ALS patients revealed disease-specific (1) intranuclear GGGGCCexp RNA foci, (2) dysregulated gene expression, (3) sequestration of GGGGCCexp RNA binding protein ADARB2, and (4) susceptibility to excitotoxicity. These pathological and pathogenic characteristics were confirmed in ALS brain and were mitigated with antisense oligonucleotide (ASO) therapeutics to the C9ORF72 transcript or repeat expansion despite the presence of repeat-associated non-ATG translation (RAN) products. These data indicate a toxic RNA gain-of-function mechanism as a cause of C9ORF72 ALS and provide candidate antisense therapeutics and candidate human pharmacodynamic markers for therapy. Copyright © 2013 Elsevier Inc. All rights reserved.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease.

              Chaperones are central to the proteostasis network (PN) and safeguard the proteome from misfolding, aggregation, and proteotoxicity. We categorized the human chaperome of 332 genes into network communities using function, localization, interactome, and expression data sets. During human brain aging, expression of 32% of the chaperome, corresponding to ATP-dependent chaperone machines, is repressed, whereas 19.5%, corresponding to ATP-independent chaperones and co-chaperones, are induced. These repression and induction clusters are enhanced in the brains of those with Alzheimer's, Huntington's, or Parkinson's disease. Functional properties of the chaperome were assessed by perturbation in C. elegans and human cell models expressing Aβ, polyglutamine, and Huntingtin. Of 219 C. elegans orthologs, knockdown of 16 enhanced both Aβ and polyQ-associated toxicity. These correspond to 28 human orthologs, of which 52% and 41% are repressed, respectively, in brain aging and disease and 37.5% affected Huntingtin aggregation in human cells. These results identify a critical chaperome subnetwork that functions in aging and disease.
                Bookmark

                Author and article information

                Contributors
                eggan@mcb.harvard.edu
                Journal
                Acta Neuropathol Commun
                Acta Neuropathol Commun
                Acta Neuropathologica Communications
                BioMed Central (London )
                2051-5960
                4 July 2018
                4 July 2018
                2018
                : 6
                : 55
                Affiliations
                [1 ]ISNI 000000041936754X, GRID grid.38142.3c, Department of Stem Cell and Regenerative Biology, , Harvard University, ; Cambridge, MA 02138 USA
                [2 ]ISNI 000000041936754X, GRID grid.38142.3c, Harvard Stem Cell Institute, , Harvard University, ; Cambridge, MA 02138 USA
                [3 ]GRID grid.66859.34, Stanley Center for Psychiatric Research, , Broad Institute of MIT and Harvard, ; Cambridge, MA 02142 USA
                [4 ]ISNI 0000 0004 0386 9924, GRID grid.32224.35, Department of Pathology, , Massachusetts General Hospital, ; Boston, MA 02114 USA
                [5 ]Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224 USA
                [6 ]ISNI 0000 0004 1936 8972, GRID grid.25879.31, Department of Biology, , University of Pennsylvania, ; Philadelphia, PA 19104 USA
                [7 ]Present address: Pfizer, Cambridge, MA 02139 USA
                Article
                555
                10.1186/s40478-018-0555-8
                6031111
                29973287
                dd0beba4-b895-4333-9b8c-befeae208924
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 14 June 2018
                : 17 June 2018
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000065, National Institute of Neurological Disorders and Stroke;
                Award ID: R01NS089742
                Award ID: R35-NS097275
                Award ID: R21NS084528
                Award ID: R01NS088689
                Award ID: R01NS063964
                Award ID: R01NS077402
                Award ID: P01NS084974
                Award ID: R35NS097273
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/100000049, National Institute on Aging;
                Award ID: P50AG016574
                Award Recipient :
                Funded by: National Institute of Environmental Health Sciences (US)
                Award ID: R01ES20395
                Award Recipient :
                Funded by: Project ALS
                Funded by: Mayo Clinic Foundation
                Funded by: FundRef http://dx.doi.org/10.13039/100012312, Robert Packard Center for ALS Research, Johns Hopkins University;
                Funded by: Target ALS
                Funded by: FundRef http://dx.doi.org/10.13039/100000971, Amyotrophic Lateral Sclerosis Association;
                Categories
                Research
                Custom metadata
                © The Author(s) 2018

                amyotrophic lateral sclerosis,c9orf72 repeat expansion,dipeptide repeat proteins,drosophila,frontotemporal dementia,frontotemporal lobar degeneration,hsf1,heat shock response

                Comments

                Comment on this article